Am J Perinatol 2010; 27(10): 775-784
DOI: 10.1055/s-0030-1254240
© Thieme Medical Publishers

Management of Ornithine Transcarbamylase Deficiency in Pregnancy

Hector Mendez-Figueroa1 , Kerri Lamance2 , V. Reid Sutton2 , Kjersti Aagaard-Tillery1 , Ignatia Van den Veyver1 , 2
  • 1Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Baylor College of Medicine, Houston, Texas
  • 2Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas
Further Information

Publication History

Publication Date:
10 May 2010 (online)

Preview

ABSTRACT

Ornithine transcarbamylase (OTC) deficiency is the most common enzymatic deficiency in the urea cycle. In catabolic states, such as the intrapartum and immediate postpartum periods, hyperammonemic comas with permanent neurological damage and death can develop. We report six cases of OTC deficiency during pregnancy managed at our institution and review the literature on OTC deficiency during pregnancy. Using the patient database from our Metabolic Clinic, pregnant OTC deficiency carriers were identified. The antenatal, intrapartum, and postpartum periods were analyzed. Corresponding literature was reviewed and an extensive multidisciplinary management plan developed. All six pregnant women had favorable outcomes. No hyperammonemic episodes occurred, and intensive care unit admissions and hemodialysis were not required. Although risk to women with OTC deficiency during the intra- and postpartum period exists, multidisciplinary management and a coherent plan usually result in successful labor, delivery, and postpartum. A comprehensive plan for patients who develop hyperammonemia is recommended.

REFERENCES

Ignatia B Van den VeyverM.D. 

Department of Obstetrics and Gynecology, Baylor College of Medicine

1709 Dryden Suite 1100, MS BCM610 Houston, TX 77030

Email: iveyver@bcm.edu